归创通桥(02190)战略收购德国Optimed公司 拓展血管介入全球制造与商业化版图
ZYLOXTBZYLOXTB(HK:02190) 智通财经网·2026-01-16 02:19

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH, marking a significant milestone in the company's globalization strategy [1] Group 1: Acquisition Details - The acquisition will occur in phases, allowing Guichuang Tongqiao to eventually acquire all remaining shares and corresponding rights of Optimed [1] - This transaction is expected to enhance Guichuang Tongqiao's global operational and delivery capabilities, providing high-quality and affordable innovative products and solutions to more patients [1] Group 2: Global Market Expansion - The deal will support Guichuang Tongqiao's international strategy, accelerating its expansion in Europe and other key overseas markets [2] - Post-transaction, both companies will integrate their commercialization platforms, including sales networks and customer service systems, to create a unified and efficient global operation [2] Group 3: Optimed Overview - Optimed is a German medical technology company focused on minimally invasive vascular and urological intervention devices, established in 1996 and currently serving over 70 countries [3] - The company has a strong reputation in the peripheral venous treatment sector, with its sinus-Venous stent product validated in the STEVECO clinical trial, showing significant improvements in patient quality of life [3] Group 4: Operational Synergies - The acquisition will enhance Guichuang Tongqiao's R&D and manufacturing capabilities in overseas markets, leveraging Optimed's production base in Germany [4] - Both companies will collaborate to improve product quality and operational efficiency, while integrating R&D resources and clinical networks to expedite the launch of clinically valuable innovative products [4] Group 5: Leadership Insights - The Chairman and CEO of Guichuang Tongqiao emphasized that the acquisition is a crucial step in the company's international strategy, aiming to create an integrated operational platform across China and Europe [5] - The CEO of Optimed highlighted the need for a more comprehensive international platform to better serve global customers and achieve long-term growth, noting the complementary strengths of both companies [5]

ZYLOXTB-归创通桥(02190)战略收购德国Optimed公司 拓展血管介入全球制造与商业化版图 - Reportify